Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Ionis Pharmaceuticals $500.3 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
Illumina $500 million notes offering
The 4.65% investment-grade notes are due 2026
Jazz Pharmaceuticals $1 billion exchangeable senior notes offering
The exchangeable notes are due 2030
McKesson $2.49 billion acquisition of controlling interest in Core Ventures
We are advising McKesson on the transaction
Owens & Minor $1.4 billion Rotech acquisition financing
We are advising the lead arrangers on the financing
Eli Lilly $5 billion notes offering
The investment-grade notes are due 2027, 2029, 2034, 2054 and 2064
ANI Pharmaceuticals $316.25 million convertible notes offering
We advised ANI Pharmaceuticals on the offering
Penumbra $100 million accelerated share repurchase
We advised Penumbra on the ASR transaction
Walgreens Boots Alliance $750 million notes offering
We advised Walgreens Boots Alliance on its debt offering
CytomX Therapeutics $58.3 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market